Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
Go back to Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias| (NASDAQ: SNDX) | Delayed: 17.53 -0.15 (0.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.68 | 52 Week High | $18.03 | |||
| Open | $17.65 | 52 Week Low | $8.97 | |||
| Day High | $17.95 | P/E | N/A | |||
| Day Low | $17.37 | EPS | $0.00 | |||
| Volume | 1,133,787 | |||||
